High-Intensity Interval Exercise in Type 1 Diabetes: Stronger Protection Against Exercise-Related Glycaemic Decline in the Postabsorptive Than Postprandial State
Posted inClinical Updates news

High-Intensity Interval Exercise in Type 1 Diabetes: Stronger Protection Against Exercise-Related Glycaemic Decline in the Postabsorptive Than Postprandial State

This clinical update reviews a new randomized crossover trial and prior literature showing that high-intensity interval exercise can attenuate glucose decline and late hypoglycaemia in adults with type 1 diabetes, particularly when performed in the postabsorptive state.
Risk Factor-Weighted Clinical Likelihood in Suspected Chronic Coronary Syndrome: Useful First-Step Triage, but Not the Whole Diagnostic Story
Posted inClinical Updates news

Risk Factor-Weighted Clinical Likelihood in Suspected Chronic Coronary Syndrome: Useful First-Step Triage, but Not the Whole Diagnostic Story

The 2024 ESC-endorsed RF-CL model improves estimation of obstructive CAD probability in symptomatic patients, safely reducing unnecessary testing, but symptom ambiguity, qualitative upper ranges, and limited capture of ischemia without obstruction remain important practical constraints.
Primary vs Specialist Palliative Care in End-Stage Liver Disease: Interpreting the 2026 Cluster Randomized Trial in the Broader Evidence Base
Posted inClinical Updates Gastroenterology Internal Medicine news

Primary vs Specialist Palliative Care in End-Stage Liver Disease: Interpreting the 2026 Cluster Randomized Trial in the Broader Evidence Base

A major 2026 cluster randomized trial shows that palliative care delivered by trained hepatologists is noninferior to specialist palliative care for improving quality of life in end-stage liver disease, supporting scalable integrated models for cirrhosis and hepatocellular carcinoma.
Fludarabine Dose Intensity, Lymphodepletion Biology, and Product-Specific Outcomes in Large B-Cell Lymphoma CAR-T Therapy: Interpreting the 2026 EBMT Registry Analysis
Posted inClinical Updates Hematology-Oncology news

Fludarabine Dose Intensity, Lymphodepletion Biology, and Product-Specific Outcomes in Large B-Cell Lymphoma CAR-T Therapy: Interpreting the 2026 EBMT Registry Analysis

A large EBMT registry study suggests that escalating fludarabine during lymphodepletion does not improve tisagenlecleucel outcomes in LBCL and may worsen survival, while axicabtagene ciloleucel retains superior efficacy at standard dosing but with more neurotoxicity.
Targeting Post-Transplant Myeloid Immune Suppression in Multiple Myeloma: Why CSF-1R Blockade May Enhance Lenalidomide Maintenance After ASCT
Posted inClinical Updates Hematology-Oncology news

Targeting Post-Transplant Myeloid Immune Suppression in Multiple Myeloma: Why CSF-1R Blockade May Enhance Lenalidomide Maintenance After ASCT

A new Blood study links relapse after myeloma ASCT to CSF-1R+ immunosuppressive marrow macrophages and shows that CSF-1R inhibition synergizes with lenalidomide in preclinical models, providing a strong translational rationale for post-transplant combination maintenance.